AGTC Hosts Topping Off Ceremony for Gene Therapy Manufacturing Facility to Celebrate the Building’s Structural Completion

2 years ago

– Facility in Alachua, Florida Is Expected to be Completed in the Fourth Quarter of 2022 – GAINESVILLE, Fla. and CAMBRIDGE,…

aTyr Pharma to Present at Upcoming Investor Conferences in May

2 years ago

SAN DIEGO, May 10, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery…

CinCor Reports First Quarter Financial Results and Provides Corporate Update

2 years ago

Topline data for baxdrostat (CIN-107) in BrigHtn Phase 2 trial for treatment-resistant hypertension (rHTN) expected in 2H 2022 Topline data…

F-star Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update

2 years ago

Four Clinical Readouts Anticipated Throughout 2022Mechanistic Data on FS118 Demonstrating Shedding Mechanism and LAG-3 Reduction Presented at the 2022 American…

Prelude Therapeutics Announces First Quarter 2022 Financial Results and Operations Update

2 years ago

Prelude remains on track for clinical data readouts and next steps for the PRMT5 program, MCL1 inhibitor PRT1419, and CDK9…

Synthetic Biologics Reports Positive Safety Data on SYN-020 Intestinal Alkaline Phosphatase Phase 1 Multiple Ascending Dose Clinical Trial

2 years ago

-Orally administered SYN-020 observed to be well tolerated across all doses in healthy volunteers- ROCKVILLE, Md., May 10, 2022 (GLOBE…

INmune Bio, Inc. Presents Data Demonstrating XPro™ Promotes Remyelination in Gray Matter at 3rd European Conference on Neuroinflammation

2 years ago

XPro™ Promotes Remyelination in a Cuprizone Model of Multiple Sclerosis(MS) by Improving Macrophage Phagocytosis (clearing) of Myelin Debris Data to be Presented on May…

NightHawk Biosciences to Present at the 4th Annual Treg Directed Therapies Summit on PTX-35

2 years ago

DURHAM, N.C., May 10, 2022 (GLOBE NEWSWIRE) -- NightHawk Biosciences (NYSE American: NHWK), a fully integrated biopharmaceutical company focused on…

Agenus Corporate Update and First Quarter 2022 Financial Report

2 years ago

Botensilimab data to be presented and Phase 2 trials to launch.AGEN1571 (ILT2) clinical trials to commence and data presented at…

MiNK Therapeutics Corporate Update and First Quarter 2022 Financial Report

2 years ago

Clinical updates from solid tumor cancers and ARDS with allo-agenT-797 are on track for 2H 2022GMP manufacturing launch in 1H…